Pfizer inks marketing, supply deal with Mylan Pharmaceuticals

Pfizer Limited (BSE: 500680) announced a marketing and supply agreement with Mylan Pharmaceuticals Private Limited, according to a filing with the Securities and Exchange Board of India (SEBI) on February 21, 2025. The agreement, approved by Pfizer's Board of Directors on February 21, 2025, grants Mylan the rights to market and sell Pfizer's Ativan and Pacitane brands within India. The arrangement will span five years, and Mylan will leverage its established presence in the Central Nervous System therapy area to enhance distribution and in-clinic promotion of the products. Commercial terms will be mutually decided between the parties. This strategic move aims to broaden the reach of Ativan and Pacitane through Mylan's established network.